Stock Track | Blueprint Medicines Soars 5% Intraday Following Raised 2025 Guidance and Strong Ayvakit Sales

Stock Track

May 03, 2025

Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.

The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.

Blueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142874353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142874353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142874353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-03 03:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142874353","market":"us","top_or_hot":-1,"title":"Stock Track | Blueprint Medicines Soars 5% Intraday Following Raised 2025 Guidance and Strong Ayvakit Sales","media":"Stock Track","content":"<p>Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.</p>\n\n<p>The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.</p>\n\n<p>Blueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Blueprint Medicines Soars 5% Intraday Following Raised 2025 Guidance and Strong Ayvakit Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Blueprint Medicines Soars 5% Intraday Following Raised 2025 Guidance and Strong Ayvakit Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-03 03:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.</p>\n\n<p>The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.</p>\n\n<p>Blueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPMC","symbol_name":"Blueprint Medicines Corporation","start_time":0,"source_url":"","article_id":"1142874353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142874353","pubTimestamp":1746214980,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Blueprint Medicines Corporation  stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BPMC":"Blueprint Medicines Corporation"},"translate_title":"股票轨迹Blueprint Medicines在上调2025年指引和Ayvakit销售强劲后盘中飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":1},"content_text":"Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.\nThe biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.\nBlueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}